VCAM1 and glaucoma: Moreover, our data showed that intravitreal injection of anti-VCAM-1 antibody effectively blocked the influx of circulating Th1 cells and alleviated retinal neurodegeneration, making it an attractive candidate for therapeutic intervention in glaucoma.